
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), announced the results from its Phase 1, healthy volunteer clinical study using […]
